
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc. demonstrated significant growth during Q3 FY25, with revenues reaching $6.8 million, marking a 76% year-over-year increase and a 78% sequential rise, largely attributed to the successful integration of the Sleep Center Network (SCN). The company's service revenue more than doubled to $4.6 million, driven by substantial gains in sleep testing and treatment-center revenue, which underscores the effectiveness of the new operational model in fostering faster adoption and revenue growth. Furthermore, with a high success rate in improving conditions for patients with obstructive sleep apnea and a strong market presence in North America, alongside the expected rapid growth in the Asia Pacific region, Vivos Therapeutics is well-positioned for continued revenue expansion in the coming quarters.
Bears say
Vivos Therapeutics Inc. experienced a year-over-year revenue decline of 9% in the first half of 2025, reflecting challenges during its transition to new sleep center operations, as revenues in Q2 FY25 were $3.8 million, falling short of expectations. The company's gross margins also decreased to 55% due to discounting and changes in product and service mix, contributing to ongoing concerns about its pricing strategy and market positioning amidst competition. Additionally, Vivos faces significant operational risks, including a history of operating losses, negative cash flows, and uncertainties regarding its ability to secure capital for expansion and achieve sustainable profitability.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares